Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: An open-label, randomized trial in Japanese children aged 6 months to 17 years

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 749-758

  Saitoh, Akihiko ^a,b,c   Nagai, Akira ^c   Tenjinbaru, Kazuyoshi ^d   Li, Ping ^e   Vaughn, David W ^e   Roman, François ^f   Kato, Tatsuo ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d Development and Medical Affairs Division   (Japan)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; H1N1; Influenza; Japanese children; Pandemic

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ACNE; ADOLESCENT; ALLERGIC RHINITIS; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; AXILLARY PAIN; CHILD; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DROWSINESS; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; JAPANESE; MALE; MYALGIA; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SEROCONVERSION; SERODIAGNOSIS; SHIVERING; SIDE EFFECT; SKIN REDNESS; SWEATING; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; VACCINATION;

EID: 84863672960     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19684     Document Type: Article

References (36)

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al.; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15; PMID:19423869; http://dx.doi.org/10.1056/NEJMoa0903810.
2. Pandemic (H1N1) 2009-update 112. Geneva: World Health Organization, August 06, 2010. Available at: http://www.who.int/csr/don/2010-08-06/en/index. html. Accessed October 26, 2011.
3. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-7; PMID:19822626; http://dx.doi.org/10.1001/jama.2009.1536.
4. Rojo JC, Ruiz-Contreras J, Fernández MB, Marín MA, Folgueira L. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J 2006; 25:596-601; PMID:16804428; http://dx.doi.org/10.1097/01.inf.0000220208.59965.95.
5. Centers for Disease Control and Prevention (CDC). 2009 pandemic influenza A (H1N1) virus infections-Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 2009; 58:913-8; PMID:19713879.
6. Ministry of Health. Labour and Welfare (MHLW); Press Release (February 05, 2010). Available at: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/ 2010/02/dl/infuh0205-05.pdf. Accessed October 26, 2011. Japanese.
7. Ministry of Health. Labour and Welfare (MHLW); Press Release (August 11, 2010). Available at: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2010/ 08/dl/infuh0811-01.pdf. Accessed October 26, 2011. Japanese.
8. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:1100-8; PMID:20096450; http://dx.doi.org/10.1016/S0140-6736(09)62126-7.
9. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al.; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. [Erratum in: N Engl J Med 2009; 361:102]. N Engl J Med 2009; 360:2605-15; PMID:19423869; http://dx.doi.org/10.1056/NEJMoa0903810.
10. Kamigaki T, Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr Influenza 2009; December 20: RRN1139. Available at: http://knol.google.com/k/taro-kamigaki/ epidemiological-characteristics-and-low/38epug6fmizmk/1#. Accessed October 26, 2011.
11. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650.
12. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66; PMID:20018364; http://dx.doi.org/10.1016/S0140-6736(09)62003-1.
13. Strategic Advisory Group of Experts on Immunization. Report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Available at: www.who.int/wer/2009/wer8430.pdf. Accessed October 26, 2011.
14. Chu DWS, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al.; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID:19683087; http://dx.doi.org/10.1016/j.vaccine.2009.07.102.
15. Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, DraméM, Roman FP. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis 2010; 10:338; PMID:21108818; http://dx.doi.org/10.1186/ 1471-2334-10-338.
16. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07) 61297-5.
17. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:1665; PMID:18301743; http://dx.doi.org/10.1371/journal.pone.0001665.
18. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014.
19. Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065.
20. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, et al. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93; PMID:20980795; http://dx.doi.org/10.4161/hv.6.11.12851.
21. Saitoh A, Tamura S, Nagai A, Tsuchida N, Sako M, Maekawa T, et al. Clinical evaluation of an AS03-adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report). [Japanese]. J Jap Pediatr Soc 2011; 115:578-84.
22. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:2649; PMID:20508026; http://dx.doi.org/10.1136/bmj.c2649.
23. Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville-Leblanc M, Garceau R, et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010; 4:171-8; PMID:20629771; http://dx.doi.org/10.1111/j.1750-2659.2010.00146. x.
24. A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101; PMID:21168369; http://dx.doi.org/10.1016/S1473-3099(10)70296-6.
25. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73; PMID:21034828; http://dx.doi.org/10.1016/j.vaccine.2010.10.038.
26. European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
27. US Food and Drug Administration. (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available at: http://www.fda.gov/cber/gdlns/ panfluvac.htm. Accessed October 26, 2011.
28. Baxter R, Jeanfreau R, Block SL, Blatter M, Pichichero M, Jain VK, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010; 29:924-30; PMID:20431425; http://dx.doi.org/10.1097/INF.0b013e3181e075be.
29. Schmidt-Ott R, Schwarz T, Haase R, Sander H, Walther U, Fourneau M, et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine 2007; 26:32-40; PMID:18022736; http://dx.doi.org/10.1016/j.vaccine.2007.10.049.30. sdsd.
30. Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann NY Acad Sci 2011; 1217:178-90; http://dx.doi.org/10.1111/j.1749-6632.2010. 05829.x; PMID:21251008.
31. Bachmann MF, Ecabert B, Kopf M. Influenza virus: a novel method to assess viral and neutralizing antibody titers in vitro. J Immunol Methods 1999; 225:105-11; PMID:10365787; http://dx.doi.org/10.1016/S0022-1759(99)00034-4.
32. Japan Pediatric Society Committee on Muscular Contracture. A report of muscular contracture. J Jpn Pediatr Soc 1983; 87:1067-105.
33. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic influenza A (H1N1) 2009 virus vaccine-conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts, December 04, 2009. Available at: http://www.who.int/csr/disease/ swineflu/meetings/sage-oct-2009/en/. Accessed October 26, 2011.
34. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011.
35. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002; 22:751-69; http://dx.doi.org/10.2165/ 00044011-200222110-00004.
36. Reed LT, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493-8.